Bristol Myers Squibb (BMY) Other Non-Current Liabilities (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Other Non-Current Liabilities data on file, last reported at $4.9 billion in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $4.9 billion, up 8.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.9 billion (up 8.4% YoY), and the FY2025 annual result was $5.0 billion, up 12.84% from the prior year.
• Other Non-Current Liabilities fell to $4.9 billion in Q1 2026 per BMY's latest filing, from $5.0 billion in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $7.3 billion in Q1 2022 and troughed at $4.5 billion in Q4 2024.
• A 5-year average of $5.8 billion and a median of $5.9 billion in 2023 frame the typical range for Other Non-Current Liabilities.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 15.46% in 2025 and fell as far as 33.5% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $6.6 billion in 2022, then slipped by 2.56% to $6.4 billion in 2023, then plunged by 30.4% to $4.5 billion in 2024, then increased by 12.84% to $5.0 billion in 2025, then slipped by 3.77% to $4.9 billion in 2026.
• Business Quant data shows BMY's Other Non-Current Liabilities at $4.9 billion in Q1 2026, $5.0 billion in Q4 2025, and $5.5 billion in Q3 2025.